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Introduction 40
While cats have become a very popular pet worldwide-with an estimated 75+ million in 41 the US alone, the assessment and treatment of pain in cats has lagged behind that of dogs monitors that record changes in acceleration associated with movement have been used as an 166 objective outcome measure of mobility in cats (Lascelles et al., 2010; Guillot et al., 2012; Gruen 167 et al., 2014) . Cats are fitted with a small accelerometer on a collar or harness, and allowed to 168 move about normally in their home environment. This the tool can discriminate between normal 169 and affected research cats (Guillot et al., 2012) , and can even be used to show treatment effects 170 in client-owned affected cats (Lascelles et al., 2007; Lascelles et al., 2010; Guillot et al., 2013; 171 Gruen et al., 2014; Gruen et al., 2016) . To understand the mal-function of the somatosensory system present with maladaptive 174 pain, methods evaluating sensorimotor function are needed. Quantitative sensory testing (QST) 175 involves the measurement of the stimulus (mechanical, thermal hot/cold, etc.) strength or frequency of application required to elicit a withdrawal or response (e.g. head turn, limb 177 withdrawal) by the patient, with the end of the test usually determined by observation of the 178 response. It is useful for semi-objectively assessing changes in sensation, especially in relation to 179 central plasticity, and its associated allodynia, hyperalgesia, enhanced temporal summation (an 180 increasing response to repetitive stimuli), etc. (Guillot et al., 2014) . While QST is in its early 181 development in cats, it can discriminate between healthy, non-affected cats, and those with OA 182 (Guillot et al., 2014) . Other methods such as the measurement of Nociceptive Withdrawal 183 Reflexes (NWR) have been explored in dogs, but not yet in cats (Bergadano et al., 2006; Hunt et 184 al., 2016) . NWR Testing measures the magnitude of the withdrawal responses to various stimuli 185 using EMG. This modality can evaluate the threshold to elicit withdrawal, in addition to the 186 effect on withdrawal latency and magnitude after delivering repeated stimuli (temporal 187 summation). Data produced are objective, as opposed to the semi-objective QST methodology. 188 NWR testing is proposed to measure central plasticity and associated changes in pain processing, 189 and affected patients are expected to have lower thresholds and higher or stronger EMG 190 responses.
192
Overall, our ability to accurately measure chronic pain is limited, and our ability to 193 measure the maladaptive component of this pain is even more restricted. As a result, diagnosis 194 and treatment of the disorder often involves 'trial and error' on the part of the clinician. 
Treatment of maladaptive pain in cats 197
In North America, there are no drugs approved for long-term use in cats with maladaptive 198 pain, and only one NSAID (meloxicam) is approved for long-term use in some parts of the 199 world. Despite recent information suggesting that NSAID therapy can partly reverse central 200 plasticity (Arendt-Nielsen et al., 2016) , it is generally accepted that the maladaptive component 201 of pain conditions is poorly responsive to NSAIDs (Edwards et al., 2016) . Because there are also 202 concerns around the potential for adverse effects from NSAIDs, interest in alternative drug 203 therapy has emerged. Currently, drug choices are based on experience in people, or because of 204 their activity on mechanisms shown to be important in rodent models of maladaptive pain. 205 Medications that have been suggested for use in cats for the treatment of maladaptive pain are 206 gabapentin, tramadol, amantadine, amitriptyline, tapentadol, flupirtine and anti-nerve growth 207 factor antibodies (Table 1) . This review outlines what is currently known about non-NSAID drug 208 treatments that may be effective for chronic or maladaptive pain in cats. Gabapentin is an analogue of the neurotransmitter γ-Aminobutyric acid (Kukkar et al., 212 2013; Patel and Dickenson, 2016) . Gabapentin exerts its effects on voltage-gated calcium 213 channels, which are found on excitatory cells such as neurons. These channels respond to 214 depolarization currents by allowing the influx of calcium ions (Dolphin, 2016) . Four subunits of 215 calcium channels have been identified, the main pore-forming α1 subunit, and the accessory α2δ, 216 β, and γ subunits (Dolphin, 2016) . Models of neuropathic pain have demonstrated an increase in 217 the α2δ-1 subunit in dorsal root ganglion (DRG) and dorsal horn neurons (Luo et al., 2001; Bauer 218 et al., 2009) . This subunit and binding target for gabapentin is responsible for guiding or 219 trafficking of α1 subunits and therefore pore assembly, indicating a vital role of the α2δ-1 subunit 220 in altered neuronal excitability and pain processing (Luo et al., 2001; Bauer et al., 2009; Dolphin, 221 2016; Patel and Dickenson, 2016) . This binding results in a decrease in the influx of calcium ions in response to an action potential, and therefore decreased neurotransmitter release or neuronal 223 excitability. Gabapentin has been advocated for the treatment of neuropathic pain in veterinary 224 species because of experience treating neuropathic pain in humans (Backonja et al., 1998; 225 Kukkar et al., 2013; Moore et al., 2014; Larsen et al., 2016) . In people it is only approved for 226 postherpetic neuralgia, and as an adjunctive therapy for partial onset seizures, which are 227 undocumented syndromes in animals.
229
The pharmacokinetics of oral (10 mg/kg) and intravenous (4 mg/kg) gabapentin in 6 adult 230 spayed female cats has been described (Siao et al., 2010) . While bioavailability varied greatly 231 (range: 49.6 -118.3%), potentially partially due to ad libitum feeding, the half-life after oral There is also a current lack of information on pharmacokinetics after repeated dosing.
241
Minimal or no plasma protein binding has been reported in other species, however this should be 242 confirmed in the cat (Radulovic et al., 1995) .
244
Currently, there are no clinical studies evaluating the efficacy of gabapentin in chronic 245 pain conditions in cats. In a study evaluating the effects of gabapentin on nociceptive thermal 246 thresholds in research cats (Pypendop et al., 2010) , six female spayed adult cats received four 247 dosages of oral gabapentin: 0 (placebo), 5, 10, and 30 mg/kg in a crossover design. Peak plasma 248 concentrations ranged from 6.3 ± 1.3 µg/mL for the 5 mg/kg dosage, to 25.5 ± 8.6 µg/mL after 249 administration of 30 mg/kg. Despite these plasma concentrations, there was no significant effect 250 on thermal thresholds. This is not unexpected as the mechanism of action gabapentin suggests it 251 would only show efficacy when α2δ-1 subunits are expressed in an abnormal, hyperalgesic state. Tramadol is an opioid-like drug that exerts its effects via many different mechanisms of subthreshold stimuli required for response) were measured at baseline, and after 21-25 days of 289 treatment. The group found that while both cohorts showed improvement in PVF, cats receiving 290 only meloxicam showed improvement in motor activity, and only cats receiving both meloxicam 291 and tramadol showed improvement (increase) in RMTS.
293
In the second study, 15 cats with radiographically confirmed OA, and five cats without 294 OA were randomized to receive either placebo or tramadol (3 mg/kg PO every 12 h) for 19 days, 295 with a crossover following a 3-month washout period (Monteiro et al., 2017) . Outcome measures 296 again included PVF, MA, and RMTS, though the PVF data set was incomplete due to technical 297 problems. The group found that both PVF and RMTS were able to discriminate between normal 298 and affected cats at baseline. They also found significant within and between-group increases in Amantadine is used both as an antiviral medication (via unknown mechanism) in human 311 medicine, as well as for treatment of Parkinson's, due to its modulatory effects on CNS 312 dopamine concentrations (Hubsher et al., 2012) . Amantadine has also been described as an N- Flupirtine is an aminopyridine drug, which is classified as a selective neuronal potassium 392 channel opener (SNEPCO; Devulder, 2010; De Vito et al., 2014) . The mechanism of action is 393 via interaction with G-protein-regulated, inwardly rectifying K+ channels (GIRKs), a class of 394 potassium channels separate from the voltage-gated family. Activation of GIRKs by flupirtine 395 results in stabilization of the membrane potential by generation of a hyperpolarizing current, and 396 thus, decreased neuronal excitability. Flupirtine also indirectly inhibits the NMDA receptor due 397 to its role as an oxidizing agent at the receptor's redox site, which maintains the magnesium 398 block on the NMDA receptor (Devulder, 2010; De Vito et al., 2014) .
400
Flupirtine has historical use in Europe for a range of painful conditions in humans, 401 including chronic pain, migraines, musculoskeletal back pain, myofascial pain, and for 402 postoperative pain (Devulder, 2010; Harish et al., 2012) . Opioid-sparing effects have also been 403 demonstrated. Unfortunately, acute hepatotoxicity (some cases requiring liver transplants) has 404 been reported in humans (Douros et al., 2013) . which revealed an ED50 of 3.5 mg/kg PO for dogs, and 3.0 mg/kg for cats (Gordon et al., 1987; 414 Nickel, 1987) . Unfortunately, the remaining evidence of efficacy is limited to non-companion 415 animal models, including efficacy in different models of pain in rodents (Kolosov et al., 2012) .
417
Flupirtine's novel mechanism of action makes it an attractive candidate for evaluation, 418 though the drug's current availability in only European and Asian countries is a limitation. Maropitant is a potent and selective neurokinin-1 receptor (NK-1R) antagonist that 452 functions as a central and peripheral anti-emetic (Hickman et al., 2008) . This receptor is also 453 shared by the ligand Substance P (SP), which has been studied for its role in inflammatory and 454 nociceptive pathways (O'Connor et al., 2004) . It is likely the knowledge that maropitant may While initial pharmacological data are available, there is currently insufficient data for 477 pain therapeutic recommendations to be made due to lack of efficacy data. Additionally, it is 478 important to note NK-1 receptor antagonists have failed clinical trials for multiple painful 479 conditions in humans (Hill, 2000) . Possible causes for this include parallel pathways in the 480 transmission of pain which reduce the importance of any one ligand or receptor, as well as a 481 misinterpretation of anxiolysis as analgesia in pre-clinical animal data (Hill, 2000) . Prostaglandin E4 receptor antagonism Frunevetmab Antibody against nerve growth factor 895 COX, cyclo-oxygenase; NMDA, N-methyl-D-aspartate 896 a Generally accepted mechanism of action. There may be differences in the cat for some of the 
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Here, the afferent signal is transmitted to the second order neuron via mono-or multi-synaptic 905 processes, and crosses over to the other side of the spinal cord, then transmitted to the brain via 906 ascending tracts in the spinal cord (red arrow), where it is interpreted as a warning of actual or 907 potential tissue damage. There is tonically active descending inhibition (green line) from the 908 CNS (channeled via the rostro-ventromedulla) that helps control whether the information from 909 the primary afferent neuron is blocked at the level of entry into the DH of the spinal cord. 
